Copper chelator (oral)

Syprine (trientine hydrochloride)

An approved treatment for Wilson Disease.

FDA Approved (1985)by Bausch Health (Syprine); generic available
Preclinical
Phase 1
Phase 2
Phase 3
Approved
1985
Drug facts

The same compound appears under different names depending on the context. Here is how to identify Trientine hydrochloride wherever you encounter it, plus the key facts at a glance.

Generic name
Trientine hydrochloride
Brand name
Syprine
Drug class
Copper chelator (oral)
Manufacturer
Bausch Health (Syprine); generic available
How it's taken
Capsules taken by mouth and swallowed whole.

An older oral copper chelator long used as second-line treatment for Wilson disease in patients who cannot tolerate penicillamine. Generic versions are widely available and remain a workhorse of long-term Wilson disease management. Requires refrigeration in its hydrochloride formulation.

Where Trientine hydrochloride fits

Standard alternative for people with Wilson disease who cannot tolerate penicillamine, which is the group its FDA label covers. It cannot be swapped dose for dose with Cuvrior (trientine tetrahydrochloride): Cuvrior's label says it is not substitutable milligram for milligram with other trientine products. Cuvrior is also approved for a different group: adults with stable Wilson disease who are already de-coppered and tolerate penicillamine. Refrigeration and dosing schedule are other practical differences.

How Trientine hydrochloride works

Oral copper chelator that binds excess copper in the body so it can be excreted in the urine, reducing toxic copper accumulation in Wilson disease

Side effects and safety

What patients report

Iron deficiency anemia (trientine also chelates iron), gastrointestinal upset, rash, and lupus-like syndrome (systemic lupus erythematosus) has been reported. Paradoxical neurologic worsening can occur in patients with neurologic Wilson disease during early treatment. Capsules require refrigeration.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Trientine hydrochloride

Capsules taken by mouth and swallowed whole. The usual starting dose is 750 to 1,250 mg a day for adults and 500 to 750 mg a day for children, divided into 2 to 4 doses, up to a maximum of 2,000 mg a day for adults and 1,500 mg a day for children 12 and under. Take on an empty stomach, at least 1 hour before or 2 hours after meals and at least 1 hour apart from other drugs, food, or milk.

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Help paying for Syprine

Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.

Your insurance
From the drugmaker
Syprine (Trientine hydrochloride)
Some details not published
Bausch Health Patient Assistance Program
  • Free medicine program

    Brand SYPRINE is on the Bausch Health PAP list. Free medicine for eligible patients with limited or no coverage, shipped home for up to 1 year.

    For: no insurance, underinsured, Medicaid · source

Good to know: Applies to brand SYPRINE only; generic trientine is made by many companies and is not covered. Bausch left certain federal Medicaid programs on Oct 1, 2025, so Medicaid may not cover Bausch brands; Medicaid patients may get them free through the PAP. A WD Rx Access copay form exists, but its posted terms expired, so current copay help is unconfirmed.

Checked on the drugmaker's official pages on September 24, 2026. Programs change; confirm with the program before you rely on it.
Charity funds for Wilson Disease
  • From a charity · Wilson Disease Association
    WDA Patient Assistance fund
    Apply directly

    Pays for: Travel and lodging (up to 7 days) for testing or treatment, for the patient and one companion, up to $2,000 per year.

    The foundation says: “Status not shown on page”
Status as each foundation showed it on September 28, 2026.

More ways to get help paying for treatment →

How Wilson disease treatments compare

Four FDA-approved medications are available for Wilson disease, plus several investigational programs in late-stage trials. Treatment choice depends on your stage (active de-coppering versus stable maintenance), your tolerance to penicillamine, whether you have neurologic or hepatic features, and your age. This chart summarizes the practical differences between the approved options.

4 FDA-approved wilson disease treatments are available: Cuprimine / Depen (penicillamine, approved 1956); Syprine (trientine hydrochloride, approved 1985); Galzin (zinc acetate, approved 1997); Cuvrior (trientine tetrahydrochloride, approved 2022). Cuprimine / Depen is typically used as historical first-line for active de-coppering. many centers now switch patients off due to side effect burden once stable..

DrugHow it worksHow it’s givenHow oftenWhere you take itTypical useFDA approved
Cuprimine / Depen
penicillamine
Copper chelator — binds copper in the body so it can be flushed out through the urine. The original Wilson disease drug.Oral capsule or tablet, taken on an empty stomach3–4 times daily during de-coppering, lower doses for maintenanceHome (oral)Historical first-line for active de-coppering. Many centers now switch patients off due to side effect burden once stable.1956
Syprine
trientine hydrochloride
You are here
Copper chelator — binds copper for urinary excretion. Generally better tolerated than penicillamine but similar efficacy.Oral capsule, taken on an empty stomach (capsules require refrigeration)2–4 times dailyHome (oral)Alternative chelator for patients who cannot tolerate penicillamine. Generic versions widely available.1985
Galzin
zinc acetate
Copper absorption blocker — induces a protein in the gut (metallothionein) that traps dietary copper before it can be absorbed.Oral capsule, taken on an empty stomach (separated from chelators)3 times dailyHome (oral)First-line maintenance therapy in many centers, particularly for presymptomatic patients identified through family screening.1997
Cuvrior
trientine tetrahydrochloride
Copper chelator — same chelating action as Syprine, with a more chemically stable salt formulation that allows simpler storage and twice-daily dosing.Oral tablet, taken on an empty stomachTwice dailyHome (oral)Approved for adults with stable Wilson disease who are de-coppered and tolerant to penicillamine; designed as a maintenance switch option.2022
Cuprimine / Depen
penicillamine · Bausch Health (Cuprimine), Mylan (Depen); generic available
MechanismCopper chelator — binds copper in the body so it can be flushed out through the urine. The original Wilson disease drug.
RouteOral capsule or tablet, taken on an empty stomach
Frequency3–4 times daily during de-coppering, lower doses for maintenance
WhereHome (oral)
Typical useHistorical first-line for active de-coppering. Many centers now switch patients off due to side effect burden once stable.
Approved1956
SyprineThis drug
trientine hydrochloride · Aton Pharma (originally Merck); generic available
MechanismCopper chelator — binds copper for urinary excretion. Generally better tolerated than penicillamine but similar efficacy.
RouteOral capsule, taken on an empty stomach (capsules require refrigeration)
Frequency2–4 times daily
WhereHome (oral)
Typical useAlternative chelator for patients who cannot tolerate penicillamine. Generic versions widely available.
Approved1985
Galzin
zinc acetate · Eton Pharmaceuticals (Galzin); generic available
MechanismCopper absorption blocker — induces a protein in the gut (metallothionein) that traps dietary copper before it can be absorbed.
RouteOral capsule, taken on an empty stomach (separated from chelators)
Frequency3 times daily
WhereHome (oral)
Typical useFirst-line maintenance therapy in many centers, particularly for presymptomatic patients identified through family screening.
Approved1997
Cuvrior
trientine tetrahydrochloride · Orphalan
MechanismCopper chelator — same chelating action as Syprine, with a more chemically stable salt formulation that allows simpler storage and twice-daily dosing.
RouteOral tablet, taken on an empty stomach
FrequencyTwice daily
WhereHome (oral)
Typical useApproved for adults with stable Wilson disease who are de-coppered and tolerant to penicillamine; designed as a maintenance switch option.
Approved2022

This chart summarizes approved Wilson disease treatments to help you understand the landscape. It is not medical advice. Treatment decisions depend on your individual disease stage, prior therapies, tolerability, and lab values for copper control. Investigational programs (ALXN1840, VTX-801, UX701) are not included because they are not yet FDA-approved. Always discuss options with your hepatologist or metabolic specialist.

Development history

Trientine hydrochloride was approved in the U.S. in 1985 as Syprine for patients intolerant to penicillamine. Generic trientine hydrochloride became available in 2018, dramatically reducing prices that had previously become controversial when Valeant raised the cost of Syprine. The newer Cuvrior (trientine tetrahydrochloride) was approved in 2022 as a more stable salt formulation.

Ask anything about Trientine hydrochloride
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Tap to start:
Or start with one of these

Explore Wilson Disease trials

Other Wilson Disease treatments

Common questions about Trientine hydrochloride

▸What is Trientine hydrochloride (Syprine)?

An older oral copper chelator long used as second-line treatment for Wilson disease in patients who cannot tolerate penicillamine. Generic versions are widely available and remain a workhorse of long-term Wilson disease management. Requires refrigeration in its hydrochloride formulation.

▸What is the mechanism of action of Trientine hydrochloride?

Oral copper chelator that binds excess copper in the body so it can be excreted in the urine, reducing toxic copper accumulation in Wilson disease

▸What are the side effects of Trientine hydrochloride?

Iron deficiency anemia (trientine also chelates iron), gastrointestinal upset, rash, and lupus-like syndrome (systemic lupus erythematosus) has been reported. Paradoxical neurologic worsening can occur in patients with neurologic Wilson disease during early treatment. Capsules require refrigeration.

▸How is Trientine hydrochloride taken?

Capsules taken by mouth and swallowed whole. The usual starting dose is 750 to 1,250 mg a day for adults and 500 to 750 mg a day for children, divided into 2 to 4 doses, up to a maximum of 2,000 mg a day for adults and 1,500 mg a day for children 12 and under. Take on an empty stomach, at least 1 hour before or 2 hours after meals and at least 1 hour apart from other drugs, food, or milk.

▸Is Trientine hydrochloride FDA approved?

Yes, Trientine hydrochloride (Syprine) is FDA approved (1985) for the treatment of Wilson Disease.

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: September 2026.

Follow Trientine hydrochloride (Syprine) news by email

One email when Trientine hydrochloride (Syprine) has trial changes, FDA news, or label updates for its condition. No newsletter, no spam.

We never share your email. Unsubscribe anytime.